Island Pharmaceuticals Limited ACN 641 183 842 | Registered office: Suite 1.01, 117 Camberwell Rd, Hawthorn East VIC 3123, Australia 19 October 2026 ASX Announcement USAMRIID Marburg NHP study advances as 22 non-human primates successfully complete screening • Screening and preparation...
USAMRIID Marburg study advances towards dosing
Filed with ASX · · 3 pages · English
Release
Island Pharmaceuticals Ltd on 6ix
Story so far
Earlier from Island Pharmaceuticals
- Galidesivir GMP manufacturing commences
- Pivotal Marburg data secured for Galidesivir FDA pathway
- Island boosts Galidesivir supply as Ebola surges
- Texas Biomed SOW accelerates pivotal FDA pathway
- Investor Presentation - Ebola Clinical Program
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals